S-Adenosyl-L-Methionine (SAMe) for Osteoarthritis of the Hands

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Dartmouth-Hitchcock Medical Center, Lebanon, NH
Osteoarthritis of the Hands+1 More
S-Adenosyl-L-Methionine (Sam-E) - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The primary objective of this study is to demonstrate the feasibility of evaluating SAMe tolerability, analgesic benefits, and daily functional improvement in patients with osteoarthritis of the hands compared to placebo. The secondary objective of this study is to generate preliminary data on discomfort, function, quality of life in patients with osteoarthritis of the hands when taking SAMe compared to placebo.

Eligible Conditions

  • Osteoarthritis of the Hands

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Weekly for 17 weeks

Weekly for 17 weeks
Determine the effect of SAMe supplementation on quality of life measures regarding hand arthritis, as measured by DASH (Disability of Arm, Shoulder and Hand) survey responses done weekly for 17 weeks
Determine the effect of SAMe supplements on hand discomfort relative to placebo, as measured by the change in discomfort scores over time on a visual analog scale
Determine tolerability of SAMe supplementation compared to placebo, as measured by a survey of 14 common symptoms one may experience from a supplement

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

S-Adenosyl-L-Methionine (SAMe)
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

40 Total Participants · 2 Treatment Groups

Primary Treatment: S-Adenosyl-L-Methionine (SAMe) · Has Placebo Group · N/A

S-Adenosyl-L-Methionine (SAMe)Experimental Group · 2 Interventions: S-Adenosyl-L-Methionine (Sam-E), Placebo · Intervention Types: Drug, Drug
PlaceboPlaceboComparator Group · 2 Interventions: S-Adenosyl-L-Methionine (Sam-E), Placebo · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: weekly for 17 weeks

Trial Background

Scott C. Jaynes, Physician Investigator
Principal Investigator
Dartmouth-Hitchcock Medical Center
Closest Location: Dartmouth-Hitchcock Medical Center · Lebanon, NH
2001First Recorded Clinical Trial
1 TrialsResearching Osteoarthritis of the Hands
335 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Objective findings of at least one hand meeting diagnostic criteria based on the American College of Rheumatology (ACR)* or existing radiographic evidence of osteoarthritis as judged by a radiologist.
You have a current primary care provider at Heater Road Primary Care.
You have been seen at the Heater Road clinic in the past 3 years.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.